Uncategorized
Spark Therapeutics posts $74.4 million quarterly loss
Spark Therapeutics reported a net loss of $74.4 million, or $2.40 per common share, in the second quarter of 2017 compared with a net loss of $28.7 million, or $1.04 per common share, in the second quarter of 2016.Research and development costs increased from $19.6 million in 2016’s second quarter to $33 million this year, which was attributed to a $9.8 million increase in internal expenses and $3.6 million increase in external research and development mostly related to Luxturna (voretigene neparvovec), according to a company press release.